Johnson & Johnson (JNJ) Stock Analysis
Healthcare · Drug Manufacturers - General
Sell if holding. Analyst target reached at $228.00 — A.R:R is negative (-0.0) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Weak growth.
Johnson & Johnson researches, manufactures, and sells healthcare products through two segments: Innovative Medicine (oncology, immunology, neuroscience, pulmonary hypertension, HIV, cardiovascular) and MedTech. Employs approximately 138,200 people worldwide; approximately 43% of... Read more
Sell if holding. Analyst target reached at $228.00 — A.R:R is negative (-0.0) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Weak growth. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.2/10, moderate confidence.
Passes 5/7 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 76d clear, semi cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $228.00 — A.R:R is negative (-0.0) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Weak growth. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $217.67. Score 5.2/10, moderate confidence.
Take-profit target: $242.27 (+6.6% upside). Prior stop was $217.67. Stop-loss: $217.67.
Analyst target reached - limited upside remaining; Weak growth; Negative momentum.
Johnson & Johnson trades at a P/E of 26.3 (forward 17.9). TrendMatrix value score: 4.7/10. Verdict: Sell.
32 analysts cover JNJ with a consensus score of 3.8/5. Average price target: $252.
What does Johnson & Johnson do?Johnson & Johnson researches, manufactures, and sells healthcare products through two segments: Innovative Medicine...
Johnson & Johnson researches, manufactures, and sells healthcare products through two segments: Innovative Medicine (oncology, immunology, neuroscience, pulmonary hypertension, HIV, cardiovascular) and MedTech. Employs approximately 138,200 people worldwide; approximately 43% of 2025 sales occurred outside the U.S., with ~23% in Europe and 15% in Asia-Pacific and Africa.